Pfizer Inc. (NYSE:PFE) Shares Sold by Redwood Investment Management LLC

Redwood Investment Management LLC lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 16.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,667 shares of the biopharmaceutical company's stock after selling 11,876 shares during the period. Redwood Investment Management LLC's holdings in Pfizer were worth $1,583,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Parsons Capital Management Inc. RI boosted its stake in Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after buying an additional 159,984 shares during the last quarter. Mcdonald Partners LLC increased its position in shares of Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock valued at $2,926,000 after acquiring an additional 9,963 shares during the last quarter. Merit Financial Group LLC boosted its position in shares of Pfizer by 60.8% during the 4th quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock worth $3,395,000 after purchasing an additional 48,397 shares during the period. Bank of Jackson Hole Trust purchased a new stake in Pfizer in the fourth quarter valued at approximately $264,000. Finally, Amplius Wealth Advisors LLC lifted its stake in Pfizer by 80.7% during the fourth quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company's stock worth $1,242,000 after purchasing an additional 20,911 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on the company. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Trading Up 1.0%

Shares of Pfizer stock traded up $0.23 during trading hours on Friday, reaching $22.83. The stock had a trading volume of 37,727,922 shares, compared to its average volume of 40,925,832. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The firm has a 50 day simple moving average of $23.65 and a two-hundred day simple moving average of $25.36. The firm has a market capitalization of $129.77 billion, a price-to-earnings ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the prior year, the business posted $0.82 EPS. The business's revenue was down 7.8% on a year-over-year basis. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.54%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.